VRDN Q3 2024 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86,000+19.4% YoY

Gross Profit

$86,000100.0% margin

Operating Income

-$83M-97069.8% margin

Net Income

-$77M-89173.3% margin

EPS (Diluted)

$-1.15

QoQ Revenue Growth

+19.4%

Cash Flow

Operating Cash Flow

-$68M

Free Cash Flow

-$68M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$772M

Total Liabilities

$64M

Stockholders' Equity

$707M

Cash & Equivalents

$200M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86,000	$72,000	+19.4%
Gross Profit	$86,000	$72,000	+19.4%
Operating Income	-$83M	-$51M	-63.0%
Net Income	-$77M	-$48M	-60.9%

Revenue Segments

Collaboration Revenue

$100,000100%